SMALL MOLECULE DRUG DISCOVERY MARKET ANALYSIS

Small Molecule Drug Discovery Market, By Therapeutic Area (Oncology, Central Nervous System, Cardiovascular, Respiratory, Metabolic Disorders, Gastrointestinal, Others), By Process (Target ID/Validation, Hit Generation and Selection, Lead Identification, Lead Optimization), By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutes, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In January 2024, Galapagos NV announced a strategic collaboration with BridGene Biosciences, Inc. to discover and develop new precision medicines for oncology targets. The collaboration will combine Galapagos' expertise in small molecule drug discovery with BridGene's IMTAC chemoproteomics technology. Galapagos will have exclusive rights for the further development and commercialization of any resulting product candidates.
In August 2023, CAS, a division of the American Chemical Society, and Molecule.one, a leader in AI-driven pharmaceutical chemistry solutions, partnered to jointly develop computer-aided synthesis design technologies. This partnership aims to accelerate early-stage drug discovery and help chemists identify novel small molecules.
In August 2022, BioDuro-Sundia and X-Chem, a leader in DEL technology for small molecule drug discovery, introduced DNA Encoded Compound Library (DEL) technology services in China to accelerate the discovery of small molecule drugs for innovative pharmaceutical companies
In July 2022, RxCelerate launched RxNfinit, a new small molecule discovery platform that combines machine learning, in silico structure modeling, and combinatorial chemistry in a novel workflow. This platform offers notable improvements over existing tools for identifying small molecule drugs targeting a wide range of proteins.